References
- O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
- Hochhaus A, Kantarjian H M, Baccarani M, Lipton J H, Apperly J F, Druker B J, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309
- Kantarjian H M, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540–3546
- Hochhaus A, O'Brien S G, Guilhot F, Druker B J, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia March 12, 2009, [Epub ahead of Print]
- Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820
- Goh H-G, Kim Y-J, Kim D-W, Kim H-J, Kim S-H, Jang S-E, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in CML patients: implication for intermittent imatinib therapy. Leuk Lymphoma 2009; 50: 944–951
- Ross D DM, Grigg A, Schwarer A, Arthur C, Loftus K, Mills A K, et al. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early. ASH Ann Meeting Abstr 2008; 112: 1102
- Rousselot P, Huguet F, Rea D, Legros L, Cayuela J M, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60
- Mahon F-X, Huguet F, Guilhot F, Legros L, Nicolini F, Charbonnier A, et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre << - Stop imatinib >>(STIM) Study. ASH Ann Meeting Abstr 2008; 112: 187